神经内镜下经鼻蝶入路手术治疗原发性颅咽管瘤的临床疗效及对术后并发症的影响

Clinical effect of neuroendoscopic transsphenoidal surgery for primary craniopharyngioma and its effect on postoperative complications

目的探究神经内镜下经鼻蝶入路手术治疗原发性颅咽管瘤的临床疗效及对术后并发症的影响。方法选取2017年6月至2020年6月本院收治的原发性颅咽管瘤患者60例,根据手术入路方式不同分为研究组与对照组,各30例。对照组采用经颅入路手术治疗,研究组则采用神经内镜下经鼻蝶入路手术治疗,比较两组手术指标、临床疗效及并发症发生率。结果研究组手术时间、切除肿瘤时间、住院时间均明显短于对照组,术中出血量少于对照组(P<0.05);研究组治疗总有效率为96.67%,高于对照组的80.00%(P<0.05);术后,研究组并发症发生率为3.33%,显著低于对照组的23.33%,差异有统计学意义(P<0.05)。结论神经内镜下经鼻蝶入路手术治疗原发性颅咽管瘤可显著缩短手术及切除肿瘤时间,操作方便,且可明显减少出血量,缩短康复进程,安全有效,值得临床推广应用。

Objective To investigate the clinical effect of neuroendoscopic transsphenoidal surgery for primary craniopharyngioma and its influence on postoperative complications.Methods 60 patients with primary craniopharyngioma admitted to our hospital from June 2017 to June 2020 were selected and they were divided into the study group and the control group according to different surgical approaches,with 30 cases in each group.The control group was treated by transcranial approach,while the study group was treated by neuroendoscopic neuroendoscopic transsphenoidal surgery.The surgical indexes,clinical efficacy and complications of the two groups were compared.Results The operative time,tumor resection time and hospitalization time of the study group were significantly shorter than those of the control group,and the amount of intraoperative blood loss was less than that of the control group(P<0.05).The operative effective rate of the study group was 96.67%,which was higher than 80.00%of the control group(P<0.05).Postoperatively,the incidence of complications in the study group was 3.33%,which was significantly lower than 23.33%in the control group,the difference was statistically significant(P<0.05).Conclusion Neuroendoscopic transsphenoidal surgery in the treatment of primary craniopharyngioma can significantly shorten the time of surgery and tumor resection,convenient operation,can significantly reduce the amount of bleeding,shorten the recovery process,safe and effective,it is worthy of clinical promotion and application.